Caligan Partners as of March 31, 2024
Portfolio Holdings for Caligan Partners
Caligan Partners holds 12 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Liquidia Corporation Com New (LQDA) | 40.4 | $153M | 10M | 14.75 | |
| Alimera Sciences Com New (ALIM) | 17.4 | $66M | 17M | 3.90 | |
| Anika Therapeutics (ANIK) | 9.6 | $37M | 1.4M | 25.40 | |
| Evolus (EOLS) | 7.0 | $26M | 1.9M | 14.00 | |
| Exelixis (EXEL) | 6.9 | $26M | 1.1M | 23.73 | |
| Verona Pharma Sponsored Ads (VRNA) | 5.5 | $21M | 1.3M | 16.09 | |
| Enanta Pharmaceuticals (ENTA) | 4.0 | $15M | 858k | 17.46 | |
| Agios Pharmaceuticals (AGIO) | 3.7 | $14M | 485k | 29.24 | |
| Y Mabs Therapeutics (YMAB) | 2.5 | $9.5M | 587k | 16.26 | |
| Outlook Therapeutics | 1.6 | $6.0M | 500k | 11.94 | |
| BioCryst Pharmaceuticals (BCRX) | 1.0 | $3.9M | 759k | 5.08 | |
| I Mab Sponsored Ads (IMAB) | 0.4 | $1.4M | 757k | 1.86 |
